In the BioHarmony Drug Report Database

"Preview" Icon

Voretigene neparvovec

Luxturna (voretigene neparvovec) is a gene pharmaceutical. Voretigene neparvovec was first approved as Luxturna on 2018-11-22. It has been approved in Europe to treat leber congenital amaurosis and retinitis pigmentosa.

 

Trade Name

 

Luxturna
 

Common Name

 

voretigene neparvovec
 

ChEMBL ID

 

CHEMBL3707275
 

Indication

 

leber congenital amaurosis, retinitis pigmentosa
 

Drug Class

 

Image (chem structure or protein)

Voretigene neparvovec structure rendering